...
首页> 外文期刊>European journal of ophthalmology >Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.
【24h】

Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.

机译:玻璃体腔注射培加他尼治疗糖尿病性黄斑水肿后后玻璃体脱离不完全。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE. Posterior hyaloid adherences play a role in the pathogenesis of diabetic macular edema (DME). Intravitreal antivascular endothelial growth factor (VEGF) drugs are presently being used to treat DME. The authors report one case of incomplete posterior hyaloid detachment (PHD) following intravitreal pegaptanib to treat DME. This case shows a combined mechanism of DME resolution by anti VEGF and PHD. METHODS. Prospective, interventional, single case report. One male patient with bilateral DME was treated by intravitreal pegaptanib in his right eye every 6 weeks for 6 months (five injections) and followed for 42 months. RESULTS. Central macular thickness decreased from 511 to 376 im at month 4 in the treated eye and remained within 10% of this value during follow-up. The posterior hyaloid became taut and partially detached after the third injection and was almost completely detached 1 year later. Visual acuity remained unchanged in both eyes during follow-up. CONCLUSIONS. PHD may play an important role in cases where macular thickness is successfully reduced or better acuity is achieved after intravitreal injections.
机译:目的。透明质酸后壁粘附在糖尿病性黄斑水肿(DME)的发病机理中起作用。玻璃体内抗血管内皮生长因子(VEGF)药物目前被用于治疗DME。作者报告了一例玻璃体腔培加他尼治疗DME后不完全的后透明样玻璃体脱离(PHD)。这种情况显示了抗VEGF和PHD分解DME的综合机制。方法。前瞻性,介入性,单例报告。一名男性双侧DME患者每6周接受玻璃体内培加他尼右眼治疗,连续6个月(五次注射),然后进行42个月。结果。在治疗的第4个月中,黄斑中央厚度从511降至376 im,并在随访期间保持在该值的10%以内。在第三次注射后,后玻璃体变得紧绷并部分脱离,一年后几乎完全脱离。随访期间两只眼睛的视力保持不变。结论。在玻璃体内注射后成功减少黄斑厚度或获得更好的敏锐度的情况下,PHD可能起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号